Yes, day-one subcutaneous Leqembi is available in 2026 for early Alzheimer's, so treatment can begin at home without prior IV infusions. For adult children, access still turns on amyloid confirmation, Medicare registry enrollment, and caregiver training with brain MRI follow-up.
Leqembi Iqlik, the name for once-weekly subcutaneous lecanemab-irmb, is an amyloid-clearing antibody for early disease. Eisai and Biogen via PR Newswire announced the FDA approval notice on July 13, 2026 for initiation dosing at home. This guide explains who qualifies, how supply works, what coverage requires, and what stays under clinician oversight.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who qualifies to start at home?
- How does day-one supply work?
- What does Medicare require and what does it cost?
- What training and clinic checks remain?
Who qualifies to start at home?
Treatment is narrow. The Alzheimer's Association lists eligibility only for adults with mild cognitive impairment or mild dementia due to Alzheimer's with elevated brain amyloid confirmed by PET or spinal-fluid testing. A memory-clinic diagnosis alone does not qualify a parent.
The evidence has a limit adult children should weigh. Drug Topics reports FDA based approval on IV CLARITY-AD results plus matching drug levels and amyloid removal, not a new long-term outcomes trial of subcutaneous start. Families should not assume identical long-term benefit data.
- confirmed mild cognitive impairment or mild dementia due to Alzheimer's
- positive amyloid PET or cerebrospinal-fluid test
- clinician review of MRI safety, medical history, and other medicines
How does day-one supply work?
The start dose is fixed. Eisai reports the initiation regimen as 500 mg once weekly given as two back-to-back 250-mg autoinjector shots of about 15 seconds each. After 18 months of IV or subcutaneous treatment, the dose changes to 360 mg once weekly for maintenance.
Supply runs outside retail pharmacies. Eisai states Leqembi Iqlik for initiation became available in the U.S. in late August 2026 through specialty pharmacy in its Leqembi Specialty Pharmacy Network. Ask the prescriber which network pharmacy will ship, store, and schedule refills.
What does Medicare require and what does it cost?
Medicare coverage has a registry condition. The Centers for Medicare and Medicaid Services states in its NCD 200.3 coverage memo that approved amyloid antibodies including lecanemab are covered only with evidence development. The parent must enroll in an approved registry or comparative study.
Wholesale cost is high, but caps and aid change the family math. Managed Healthcare Executive reports its price and coverage summary lists $385 per autoinjector, or $770 per initiation week. The same source lists a $2,100 Medicare Part D 2026 out-of-pocket cap with monthly smoothing, plus Eisai $0-copay aid up to $10,000 per year and free-drug help for eligible uninsured patients.
What training and clinic checks remain?
Home does not mean solo. Medscape Medical News notes the patient or caregiver may give the shots after training with the Instructions for Use video and Welcome Kit. Practice handling, timing the two shots, skin checks, storage, missed-dose rules, and who to call.
Clinic safety follow-up stays mandatory. The same source notes scheduled brain MRI scans for ARIA, discussion of APOE-epsilon-4 risk, and clinician oversight remain required. Confirm the MRI dates, APOE test plan, and after-hours contact before the first home dose ships.
You Might Also Like
- Serious Illness and End-of-Life Dementia Research Priorities in 2026: Cost and Access Questions for Adult Children
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: A Source-Checked Briefing for Memory Clinic Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: A Source-Checked Briefing for Memory Clinic Patients
